Connor Iapoce

David M. Brown, MD, discusses the full one-year data from the PULSAR and PHOTON trials and the implications of aflibercept 8 mg for patients with AMD and DME.

NCX 470 0.1% eye drops reduced IOP more than latanoprost in individuals with open-angle glaucoma or ocular hypertension in the phase 3 Mont Blanc trial.

Elevated Lp(a) may influence LDL-C levels and prevent LDL-C target achievement in patients at very high cardiovascular risk.

Measurement of reticulocyte hemoglobin equivalent is cost-effective and could be a useful marker of iron deficiency in acute decompensated heart failure.

A recent comparison of changes in Lp(a) mass and molar concentrations found that each assay method was similarly predictive of MACE reductions with alirocumab.

Results from the PHEDRE study show nitrous oxide in a gas mixture for pain was not problematic for most patients with sickle cell disease in France.

Metformin demonstrated a protective effect against new-onset geographic atrophy, which persisted and was more pronounced in individuals without diabetes.

Iron deficiency, independent of anemia, may be a potentially modifiable target to improve patient-reported outcomes after kidney transplantation.

A cohort analysis in the UK observed no significant association between sildenafil use and AMD prevention in men with erectile dysfunction.

A cross-sectional analysis of nine low- and middle-income countries revealed few statistically significant associations between anemia and early childhood development.

A post-hoc analysis of the Ocular Hypertension Treatment Study shows the inclusion of a PRS improved the prediction of POAG onset in patients with ocular hypertension.

Oral minocycline was not associated with a decrease in GA enlargement over 24 months, compared with the run-in phase, in a recent phase 2 nonrandomized trial.

Nesvategrast was safe and well tolerated but did not exhibit a statistically significant impact on the severity or progression of diabetic retinopathy in the phase 2 DR:EAM trial.

Iptacopan monotherapy improved hematologic outcomes in both anti-C5–treated patients with persistent anemia and those not treated with complement inhibitors across two phase 3 trials.

In a registry-based analysis, more hospitalized children with SCD and COVID-19 had severe infection requiring supplemental oxygen, compared with the general population.

The 2016 CDC guidelines led to significant decreases in opioid prescriptions and an increase in pain-related healthcare utilization for people with sickle cell disease.

An analysis of an FDA adverse event database found thrombotic adverse events were more frequently reported with emicizumab than those of FVIII products.

Patients in France with hemophilia A who switched their FVIII replacement treatment trended towards fewer bleeding events and articular non-bleeding events requiring hospitalization.

Iron deficiency marks more than a comorbidity in heart failure, with adverse manifestations, including anemia and a higher risk of mortality, influencing the clinical trajectory of patients with HFrEF.

A water-free cyclosporine ophthalmic solution (SHR8028) more effectively improved total corneal fluorescein staining versus vehicle, but showed no superiority in dryness score, in phase 3 findings.

Published one-year results from PULSAR and PHOTON show extended dosing regimens with aflibercept 8 mg were non-inferior to aflibercept 2 mg for treating wet AMD and DME.

Continuous glucose monitoring was associated with lower odds of diabetic retinopathy development, even after adjusting for hemoglobin A1c levels.

People of increasing age and worse socioeconomic status were more likely to be unwilling-in-principle to participate in home-monitoring vision tests.

Initiation of SGLT2 inhibitors reduced the risk of composite anemia outcomes, compared with GLP-1 RA, among patients with type 2 diabetes and CKD.

In new topline results from the KARDIA-2 trial, zilebesiran added to standard-of-care antihypertensive treatments showed significant reductions in systolic blood pressure.

Clobetasol propionate ophthalmic suspension 0.05% for post-ocular surgery pain marks the first new steroid in the ophthalmic market in over 15 years.

A secondary analysis of cross-sectional data found that serum albumin levels negatively correlated with the prevalence of diabetic retinopathy.

Our February 2024 ophthalmology month-in-review features an in-depth look into global vision loss rates, a new clinical quiz on AAO guidelines, and two episodes of our flagship ophthalmology podcast, New Insight with Veeral Sheth, MD.

In a post hoc analysis of the ACCT-2 study, a risk profile using simple hematologic parameters identified patients hospitalized with COVID-19 who benefited most from baricitinib treatment.

The newest version of ChatGPT accurately responded to most multiple-choice questions on ophthalmic cases but performed better on non-image–based questions.